Lv1
40 积分 2024-04-10 加入
A neomorphic protein interface catalyzes covalent inhibition of RAS G12D aspartic acid in tumors
2天前
已完结
Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial
4天前
已完结
Neoadjuvant Concurrent Chemo–Immuno–Radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 NSCLC: Primary Results From the SQUAT Trial (WJOG 12119L)
11天前
已完结
Neoadjuvant atezolizumab and chemotherapy in patients with resectable non-small-cell lung cancer: an open-label, multicentre, single-arm, phase 2 trial
17天前
已完结
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer
4个月前
已完结
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
4个月前
已完结
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
4个月前
已完结
Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study
4个月前
已完结
Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function
5个月前
已完结
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
